Breaking the mold: Overcoming resistance to immune checkpoint inhibitors

Immune checkpoint blockade-based therapies are effective against a sorts of cancers. However, drug resistance is a problem that cannot be ignored. This review intends to elucidate the mechanisms underlying drug tolerance induced by PD-1/PD-L1 inhibitors, as well as to outline proposed mechanism-based combination therapies and small molecule drugs that target intrinsic immunity and immune checkpoints. According to the differences of patients and types of cancer, the optimization of individualized combination therapy will help to enhance PD-1/ PD-L1-mediated immunoregulation, reduce chemotherapy resistance, and provide new ideas for chemotherapyresistant cancer.

Automated summary

This review focuses on the mechanisms underlying drug tolerance induced by PD-1/PD-L1 inhibitors and proposes mechanism-based combination therapies and small molecule drugs that target intrinsic immunity and immune checkpoints. Optimization of individualized combination therapy can enhance PD-1/PD-L1-mediated immunoregulation, reduce chemotherapy resistance, and offer new ideas for chemotherapy-resistant cancer.